Archive Newsletter
-
08.28.26 -- What Goes Into Restarting A Shelved Orphan Drug Candidate?
8/28/2026
08/28/26 Cell & Gene Newsletter
-
08.27.26 -- Meeting Modern Challenges In Ophthalmic Drug Delivery
8/27/2026
08/27/26 Cell & Gene Newsletter
-
08.26.26 -- Optimizing Cold Chain & Cryo Logistics
8/26/2026
08/26/26 Cell & Gene Newsletter
-
08.26.26 -- Clinical Success Of Combination Cell Therapy Hinges On Manufacturability
8/26/2026
08/26/26 Cell & Gene Newsletter
-
08.25.26 -- OPCU: Advancing Large Molecule Programs Through Smarter Fill-Finish Planning
8/25/2026
08/25/26 Cell & Gene Newsletter
-
08.25.26 -- Why Vector Yield Remains The Biggest Bottleneck In Vivo Gene Therapy
8/25/2026
08/25/26 Cell & Gene Newsletter
-
08.25.26 -- Reimagine Solid Tumor Immunotherapy With SRC-3-Edited Tregs
8/25/2026
08/25/26 Cell & Gene Newsletter
-
08.24.26 -- The Decision Rights Matrix: Making Sponsor-CDMO Governance Enforceable
8/24/2026
08/24/26 Cell & Gene Newsletter
-
08.21.26 -- Smarter Workflows For Cell & Gene Production
8/21/2026
08/21/26 Cell & Gene Newsletter
-
08.21.26 -- Rewriting The Playbook For Stargardt Disease With Shannon Boye, Ph.D.
8/21/2026
08/21/26 Cell & Gene Newsletter